FDA says clinical data for UniQure's Huntington's disease therapy not adequate
03/11/2025 12:17
Nov 3 (Reuters) - UniQure QURE.O, UQ1.F said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to support its marketing application, according to the U.S. Food and Drug Administration. (Reporting by Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal